发酵乳杆菌
益生菌
失调
阿克曼西亚
肠道菌群
肥胖
乳酸菌
生物
拟杆菌
微生物群
免疫学
炎症
医学
微生物学
内科学
细菌
生物信息学
乳酸
遗传学
植物乳杆菌
作者
José Alberto Molina‐Tijeras,Patricia Diez‐Echave,Teresa Vezza,Laura Hidalgo-García,Antonio Jesús Ruiz‐Malagón,María Jesús Rodríguez‐Sojo,Miguel Romero,Iñaki Robles‐Vera,Féderico García,Julio Plaza‐Díaz,Mónica Olivares,Juan Duarte,María Elena Rodríguez‐Cabezas,Alba Rodríguez‐Nogales,Júlio Gálvez
标识
DOI:10.1016/j.phrs.2021.105471
摘要
Obesity is one of the main features of metabolic syndrome, where a low-grade chronic inflammation and gut dysbiosis contribute to the development of the related metabolic dysfunctions. Different probiotics have demonstrated beneficial effects on this condition, increasing the interest in the development of probiotic treatments. Lactobacillus fermentum CECT5716 has shown anti-inflammatory effects and capacity to modulate microbiota composition in different experimental models. In this study, L. fermentum CECT5716 was evaluated in a model of high fat diet-induced obesity in mice. It exerts anti-obesity effects, associated with its anti-inflammatory properties and amelioration of endothelial dysfunction and gut dysbiosis. The probiotic restores Akkermansia sp. abundance and reduced Erysipelotrichi class and Clostridium spp presence as well as increased Bacteroides proportion. In conclusion, this probiotic represents a very interesting approach. Our findings describe, for the first time, the ability of this probiotic to ameliorate experimental obesity through microbiome modulation, affecting different bacteria that have been reported to play a key role in the pathogenesis of obesity. Therefore, this suggests a potential use of L. fermentum CECT5716 in clinical practice, also taking into account that probiotic treatments have demonstrated to be relatively safe and well tolerated.
科研通智能强力驱动
Strongly Powered by AbleSci AI